At the October 1, 2026, Noble Capital Markets virtual conference, Sernova and Seraxis described their proposed merger into BetaNova Biotherapeutics: Seraxis’ stem-cell-derived islet-cell programs and manufacturing would be combined with Sernova’s implantable Cell Pouch. As of October 3, the merger had not been reported as completed. The companies projected a November 2026 close, subject to approvals and other conditions, and outlined clinical milestones that remain plans rather than achieved results.
What Sernova and Seraxis announced at the conference
Sernova announced on September 25 that its President and CEO Jonathan Rigby and Seraxis President and CEO Will Rust, Ph.D., would give a joint presentation and fireside-style Q&A at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 1, 2026, at 1:30 p.m. Eastern. The company said they would discuss the proposed merger and the combined company’s strategy. Sernova said a replay would be available for 90 days through Sernova and Channelchek.
Investing.com published a transcript of the October 1 session. Rigby and Rust discussed the proposed combination, the cell programs, the Cell Pouch, immune management and clinical plans. Their remarks describe company strategy and expectations; they are not independent validation of clinical efficacy, manufacturing advantages or potential patient benefit.
What the proposed merger would create
On September 8, 2026, Sernova and Seraxis announced a definitive agreement to combine their businesses and technologies in a proposed U.S.-domiciled clinical-stage company called BetaNova Biotherapeutics. Its stated focus is islet-cell replacement for type 1 diabetes. The transaction is structured as a statutory plan of arrangement under British Columbia’s Business Corporations Act.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Scan for outdated or missing drivers - takes under a minute3Repair Windows errors before they cause bigger problems#1 Best Overall
- Read Before You Buy — No Video Output: These adapters support charging and USB 2.0 data transfer, but cannot transmit video signals. Except for standard USB webcams (which use USB data only), they are not compatible with HDMI/DisplayPort cables, video-capable USB-C hubs, or docking stations with video output.
- Convert USB-A Ports to USB-C: Designed to connect USB-C earphones, cables, flash drives, card readers, and other USB-C accessories to standard USB-A ports. Plug-and-play with no drivers or software required.
- Aluminum Alloy Housing: Built with a sturdy aluminum alloy shell that aids in heat dissipation and protects against daily wear and scratches. Designed to maintain a stable and secure connection.
- Compact & Travel-Friendly: The ultra-compact design allows the adapter to stay plugged into your device without blocking adjacent ports or adding bulk, reducing wear and tear on your original USB ports.
- 12-Month Warranty: Backed by a 12-month manufacturer warranty for peace of mind. Designed to meet strict quality control standards for reliable everyday performance.
The proposed platform brings together distinct capabilities: Seraxis’ investigational islet cells and in-house cGMP manufacturing, Sernova’s implantable and retrievable Cell Pouch, and an immune-management strategy discussed by management. Those pieces are intended to address different challenges in cell replacement. The Cell Pouch is designed to provide a vascularized environment for therapeutic cells; it does not supply the cells itself.
Proposed ownership and financing
| Term | What the September 8 company announcement said |
|---|---|
| Post-merger ownership | Shareholders of Sernova and Seraxis were each expected to own approximately 50% of BetaNova after completion. This is a group-level estimate, not an individual shareholder’s exchange calculation. |
| Sernova shareholders’ Seraxis interest | They were expected collectively to hold approximately 50% of Seraxis’ issued and outstanding shares on a non-diluted basis. |
| Convertible-note financing | The companies said they had secured commitments for US$10 million from existing insider shareholders. The financing round was announced as open to additional qualified investors through September 30, 2026. Notes were to convert automatically into non-voting BetaNova common stock on completion; the announcement does not establish that conversion had occurred by October 3. |
| Break fee and deal protections | The release disclosed a US$5 million break fee payable in certain circumstances, customary deal protections and a possible ability for Sernova to consider an unsolicited superior proposal, subject to a right to match. |
| Financial adviser | Noble Capital Markets was named as exclusive financial adviser. |
Approvals, timing and proposed listings
The September 8 announcement projected a November 2026 closing, conditional on required Sernova and Seraxis shareholder approvals, final TSX approval, court approval, required third-party consents and waivers, and customary closing conditions. Sernova’s shareholder meeting was expected in the fourth quarter of 2026.
The release specified approval by at least 66⅔% of votes cast by the relevant Sernova shareholders voting together as a class, plus a simple majority excluding shares required to be excluded under MI 61-101. Director and officer support agreements were said to represent 10.8% of Sernova’s outstanding common shares. The Investing.com conference transcript reports management saying it expected a December vote and believed enough votes were secured; those remarks are not a confirmed meeting date or voting result.
Rank #2
- 5-in-1 USB-C Hub: Experience comprehensive connectivity featuring a Power Delivery input, two USB-A 2.0 ports, a USB-A 3.0 port, and an HDMI port. (Note: The USB-C power delivery input port is only for connecting an external wall charger to power your laptop and cannot power peripheral devices.)
- 90W Pass-Through Charging: Achieve optimal charging with 90W pass-through power to your laptop, supported by a total input of 100W, with the hub reserving 10W for operational efficiency. (Note: Wall charger not included.)
- Quick Data Transfers: Accelerate your productivity with rapid data transfers using a high-speed 5Gbps USB 3.0 port and two 480Mbps USB 2.0 ports.
- 4K HDMI Display: Enhance your visual experience with a hub capable of delivering 4K resolution at 30Hz in both mirror and extend modes. Please note that this hub is compatible with MacBook (macOS 12 and newer), Windows 10 and 11, ChromeOS, and laptops equipped with DP Alt Mode and Power Delivery. Note: This device is not compatible with Linux.
- What You Get: Anker USB-C Hub (5-in-1, 4K HDMI), welcome guide, 18-month warranty, and our friendly customer service.
BetaNova also intended to seek a Nasdaq listing in the first quarter of 2027, subject to applicable requirements and approvals. The release described an expected TSX listing for Seraxis/BetaNova stock, also subject to TSX requirements and final approval. Neither listing was assured by the announcement.
How the proposed therapy platform fits together
SR-02: the initial cell candidate
SR-02 is Seraxis’ allogeneic, stem-cell-derived pancreatic islet candidate. “Allogeneic” means the cells are intended for use in a recipient other than the person from whom they originated. Seraxis said the FDA had cleared an investigational new drug application (IND) for a type 1 diabetes trial in April 2026. The proposed strategy pairs the cells with immune management intended to establish tolerance and reduce the need for immunosuppression; that intended outcome has not been established clinically.
SR-03: a gene-edited follow-on
SR-03 is a follow-on islet-cell candidate with gene edits that the companies say are intended to improve compatibility and enable immune evasion. The development goal of reducing or eliminating immunosuppression is an objective, not a demonstrated clinical result. The companies’ September announcement projected an SR-03 IND in the second half of 2027.
Rank #3
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
Cell Pouch: a place for therapeutic cells
Sernova’s Cell Pouch is an implantable, retrievable device designed to create a vascularized environment for therapeutic cells. The rationale described by the companies is to support cell survival, engraftment and function; retrievability may also be relevant to safety planning. The device and the cell candidates serve different roles, so the combination is not simply a delivery device containing a proven therapy.
Manufacturing and immune management
Seraxis contributes in-house cGMP manufacturing. In the conference transcript, management discussed immune-suppressive medicines and co-stimulatory blockers, including tegoprubart, and named a collaboration with Eledon Pharmaceuticals. These are elements of the development approach described by management, not evidence that the combined platform can avoid immunosuppression or will produce a specific clinical outcome.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
What is known about clinical evidence—and what is not
Sernova’s September 8 release said treatment and follow-up in its Phase 1/2 study of the Cell Pouch with human donor pancreatic islets in people with type 1 diabetes were complete, and that all primary and secondary endpoints had been met. The release also referred to more than 30 years of cumulative patient safety data supporting the platform’s clinical profile. These are company-reported claims; the cited release did not enumerate every endpoint definition or provide the underlying dataset in the material summarized here.
Rank #4
- Dual Converters, Infinite Potential：Includes 2× USB C male to USB A female adapters and 2× USB A male to USB C female adapters. Perfect for a wide range of uses—tablets with Bluetooth keyboards, expand USB ports on macbook, and more. Two different converters for all your daily needs
- Next-Level 10Gbps & 3A Charging: No more slow 480Mbps, this usb to usb c adapter has a transfer speed of up to 10Gbps, allowing you to do more transferring in less time. This usb adapter fits both USB A and USB C charger, supporting up to 3A fast charging
- Upgraded Exquisite Craftsmanship: With an aluminum alloy housing and metal connector, the usbc to usb adapter is extremely durable and sturdy. Rigorously tested to withstand more than 10,000 times of plugging and unplugging, ensuring long-lasting performance
- Broad Compatible: The usb c to usb adapter widely supports all USB C/ USB A devices like laptops, tablets, cellphones, car chargers, and phone chargers. Such as compatible with MacBook Pro/Air 2023/2022, Thunderbolt 4/3 Devices,Apple MagSafe Watch 9/8/7/SE/Ultra, iPad Pro 2022/2021, Samsung Galaxy S23/S20/S10, and iPhone 17/16/15 Pro. Plug and play
- Please Note: To reach 10Gbps speed, keep the cable under 3.3 ft. For USB A Male to USB C adapters, try flipping the USB C connector. USB C Male to USB A adapters support bidirectional 10Gbps transfer within 3.3 ft
In the conference transcript, management said islets remained present and functioning after five years in the Cell Pouch study. That is an attributed management statement, not independent confirmation or proof of a cure. The study involved human donor islets in the Cell Pouch; it should not be treated as clinical evidence that the proposed SR-02 or SR-03 combinations work.
The merger announcement described SR-02 as a planned Phase 1/2 trial expected to dose patients in the first quarter of 2027, with data anticipated by mid-2027. During the conference, management described an initial study enrolling six patients, with dosing targeted for early 2027 and initial data anticipated in the first half of 2027. These are forward-looking plans, not evidence that enrollment, dosing or data release had occurred by October 3.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Milestones to watch
- Shareholder and court process: whether the required Sernova and Seraxis approvals and court approval are obtained, alongside final TSX approval and the other stated closing conditions.
- Transaction close: whether completion occurs on the companies’ projected November 2026 schedule. A projected date is not a completed transaction.
- SR-02 trial start and early data: whether the planned six-patient initial study begins dosing in early 2027 and reports data on the company’s anticipated first-half or mid-2027 timetable.
- SR-03 development: whether the company advances toward the projected second-half 2027 IND and what evidence supports its immune-evasion approach.
- Listing intentions: whether the proposed Nasdaq and TSX listing plans satisfy applicable requirements and receive required approvals.
Rust’s short summary of the challenge in the conference transcript was: “What it really comes down to is execution.” For investors, execution means tracking the conditions, dates and evidence above separately rather than treating the announced strategy as proof of a completed merger or successful therapy.
Quick wins for a faster PC:
Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Repair Windows errors before they cause bigger problemsFix Now →Best Value
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
What the conference does—and does not—establish
The conference provides management’s explanation of why the companies believe their capabilities could be complementary. It does not establish that BetaNova had been formed, that the merger vote had passed, that a listing was secured, or that SR-02 or SR-03 was effective. The announced “functional cure” language is a therapeutic aspiration: the merger announcement quoted Rigby saying the combination could bring the companies “closer to a functional cure.” It is not a claim that a functional cure has been achieved.
The proposed programs also remain at different development stages: SR-02 had an IND clearance announcement and a planned early clinical trial, while SR-03 was a follow-on program with a projected future IND. The available conference and company materials do not support a head-to-head efficacy comparison between them or a conclusion about which patients would be suitable or contraindicated. Patient eligibility would depend on clinical-trial protocols and medical evaluation, not on the conference’s broad discussion of potential patient populations.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
